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Abstract: The majority of breast cancers express the estrogen receptor (ER) and are dependent
on estrogen for their growth and survival. Endocrine therapy (ET) is the standard of care for
these tumors. However, a superior outcome is achieved in a subset of ER positive (ER+)/human
epidermal growth factor receptor 2 negative (HER2 ) metastatic breast cancer patients when ET is
administrated in combination with a cyclin-dependent kinases 4 and 6 (CDK4/6) inhibitor, such as
palbociclib. Moreover, CDK4/6 inhibitors are currently being tested in ER+/HER2+ breast cancer and
reported encouraging results. Despite the clinical advances of a combinatorial therapy using ET plus
CDK4/6 inhibitors, potential limitations (i.e., resistance) could emerge and the metabolic adaptations
underlying such resistance warrant further elucidation. Here we investigate the glucose-dependent
catabolism in a series of isogenic ER+ breast cancer cell lines sensitive to palbociclib and in their
derivatives with acquired resistance to the drug. Importantly, ER+/HER2  and ER+/HER2+ cell
lines show a di↵erent degree of glucose dependency. While ER+/HER2  breast cancer cells are
characterized by enhanced aerobic glycolysis at the time of palbociclib sensitivity, ER+/HER2+ cells
enhance their glycolytic catabolism at resistance. This metabolic phenotype was shown to have
prognostic value and was targeted with multiple approaches o↵ering a series of potential scenarios
that could be of clinical relevance.
Keywords: palbociclib; metabolic reprogramming; breast cancer; Warburg metabolism; resistance
1. Introduction
The majority of breast tumors are positive for estrogen receptor alpha (ER) and negative for
human epidermal growth factor receptor 2 (HER2) and are, therefore, dependent on estrogen (E2) for
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their growth. Di↵erent endocrine therapies (ET) have been developed to target the ER pathway and
have been used e↵ectively in the clinic in the last decades. Recently, clinical trials have shown superior
outcomes in ER+/HER2  patients receiving a cyclin-dependent kinases 4 and 6 (CDK4/6) inhibitors in
combination with standard ET [1–4]. This led to regulatory approval for the use of CDK4/6 inhibitors
in the clinic for patients with ER+/HER2  metastatic breast cancers both as first- and second-line
therapy [5] contributing to their widespread use within this indication. It is foreseen that the use of
these compounds will increase in the future, potentially extending their application to the whole cohort
of ER+ patients.
Palbociclib (Ibrance, PD-0332991), the first CDK4/6 inhibitor synthesized and tested in clinical
trials, is currently indicated in combination with ET both as first- and second-line therapeutic option in
patients with ER+/HER2  breast cancer [5] and is under investigation for the treatment of patients with
ER+/HER2+ disease. However, despite the promising clinical advances with CDK4/6 inhibitors, 15% of
the ER+/HER2  breast cancer patients show de novo or early CDK4/6 inhibitors resistance and 50%
develop clinical resistance with progression within 25 months [6]. Understanding the mechanisms
involved in CDK4/6 inhibitors’ resistance is, therefore, an important biological and clinical need.
It has been previously reported that CDK4/6 inhibitors’ resistance is characterized by deregulated
molecular mechanisms that could occur on cell-cycle related hubs, e.g., loss of Rb, amplification of
p16, CDK2, 4, 6, CCNE1, 2, and overexpression of CDK7, MDM2, WEE1. These mechanisms have
been extensively reviewed in [7,8]. Moreover, emerging data in preclinical models have indicated that
metabolic deregulation could guide palbociclib response [9] suggesting that metabolic reprogramming
could be involved also in the establishment of the resistant phenotype.
Importantly, metabolic deregulation occurs in tumorigenesis and targeting bioenergetic alterations
sensitizes cancer cells to chemo- and biological therapies. Since CDK4 and CDK6 control key
metabolic regulators in physiological and pathological conditions and manipulating metabolic
pathways in addition to CDK4/6 inhibition is beneficial in cancer [9–12], we investigated the metabolic
reprogramming that occurs in a panel of isogenic ER+ breast cancer cell lines in response and adaptation
to palbociclib.
The current study highlights the metabolic changes occurring in glucose exploitation in ER+
breast cancer cells that are exposed (+PD) or have acquired resistance to palbociclib (PDR). Crucially,
we demonstrated that ER+/HER2+ and ER+/HER2  breast cancer cells rely on aerobic glycolysis
di↵erently when mimicking a sensitive or a resistant clinical scenario, hence targeting glucose
metabolism can re-sensitize ER+/HER2+ PDR cells to palbociclib and significantly enhance its
anti-tumoral e↵ects in ER+/HER2  sensitive cells.
2. Materials and Methods
2.1. Cell Lines and Reagents
T47D and ZR75-1 (ER+/HER2 ) human breast cancer cell lines were obtained from Dr Livia
Malorni, CNR Avellino, Italy; MCF7 (ER+/HER2 ) human breast cancer cells were purchased from
ATCC; ER+/HER2+ MDA-MB-361 cells were purchased from Sigma-Aldrich and BT474 cells from
Interlab Cell Line Collection, Genova, Italy. In January 2016, all cell lines and their PDR derivatives
have been authenticated by short tandem repeat DNA profiling analysis. Cell lines were maintained
in Dulbecco’s Modified Eagle Medium (DMEM, Euroclone, Pero, Italy) supplemented with 10%
fetal bovine serum (FBS, Euroclone), 2 mM glutamine (Sigma, Merck, Darmstadt, Germany) and 1%
penicillin/streptomycin (Sigma). The palbociclib-resistant derivatives (PDR cells) were cultured in the
same condition in the presence of 1 µM palbociclib (Pfizer, Pfizer Italia, Latina, Italy), as previously
described [13]. Cells were amplified, stocked, frequently subjected to mycoplasma testing and once
thawed were kept in culture for a maximum of 20 passages. To evaluate cell viability under glucose
deprivation or galactose treatment, the cellswere cultured in deprived-DMEM1X (Gibco, ThermoFisher
Scientific, Monza, Italy), supplemented with or without 25 mM glucose (Sigma) in the presence of 10%
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FBS, 2mM glutamine and 110 mg/L pyruvate (Sigma). 2-deoxy-glucose (2-DG, Sigma) and galactose
(Sigma) were used at the concentration of 5 mM and 25 mM, respectively.
2.2. Immunoblotting
Breast cancer cells were washed with phosphate-bu↵ered saline (PBS) and lysed in ice using
Laemmli Sample Bu↵er 1X (Biorad, Milano, Italy) supplemented with protease inhibitors (Sigma)
and protein concentrations were measured by BCA method. 20–40 µg of total proteins were loaded
in precast sodium dodecyl sulfate–polyacrylamide gel electrophoresis (SDS-PAGE) gels (Biorad)
and then transferred onto nitrocellulose membrane by Trans-Blot Turbo Transfer Pack (Biorad).
The immunoblots were incubated in non-fat dry milk 2%, Tween-20 0.05% in PBS at room temperature
for 1 h and then probed with primary and appropriate secondary antibodies. The antibodies used in
this work were GLUT1 and HKII (#12939 and #2867, dilution 1:1000, Cell Signaling Technology, Leiden,
The Netherlands), MCT1 and MCT4 (sc-365501 and sc-50329, dilution 1:500, Santa Cruz Biotechnology,
Heidelberg, Germany) and Tubulin (T5168, dilution 1: 15000, Sigma).
2.3. Quantitative Real-Time Polymerase Chain Reaction (qRT-PCR)
Total RNA was extracted using RNeasy (RNeasy plus kit, Qiagen, Milano, Italy), quantified using
Nanodrop 1000 (Thermo Scientific) and 500 ng were reverse transcribed, prior to gDNA removal,
to obtained cDNAusing the QuantiTect cDNA reverse transcription kit (Qiagen). Quantitative real-time
polymerase chain reaction (qRT-PCR) was performed using the CFX96 Touch Real-Time PCR Detection
System (Biorad) using Taqman gene expression assay (Applied Biosystem, Thermo Fisher Scientific).
The probes used are HKII (Hs0060686_m1) and GLUT1 (Hs00892681_m1). Data were normalized
on Glyceraldehyde 3-Phosphate Dehydrogenase GAPDH (Hs02786624_g1) and TATA-Box Binding
Protein TBP (Hs00427620_m1). The relative quantity was determined using DDCt by the CFX Maestro
software (BioRad).
2.4. Cell Viability Assays
Parental and PDR cells were seeded into 12- or 24-well plates and subjected to the
experimental procedures such as RNA interfering or glycolysis impairment as described in the
Figures and relative legends. 3 days post-procedure (i.e., RNAi transfection, drug administration
or culture conditions changes), plates were stained with crystal violet (triphenylmethane dye
4-[(4-dimethylaminophenyl)-phenyl-methyl]-N,N-dimethyl-alanine, Sigma), dried overnight and
the crystal violet within the adherent cells was solubilized using 500 µL/well of 2% SDS. The absorbance
was evaluated at 595 nm using a microplate reader. Alternatively, cell viability was also assessed
by MTT (3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyl tetrazolium bromide, Sigma) assay. Living cells
were stained with 10 mg/mLMTT dissolved in full medium and incubated at 37  C in a humidified
atmosphere incubator containing 5% CO2 for 3 h. The incorporated amount of MTT was resuspended
in dimethyl sulfoxide DMSO and quantified measuring absorbance at 550 nm using a microplate reader.
2.5. RNAi Transfection
PDR cells were seeded into 6-well plates (5 ⇥ 105 per well) to have a 70% of confluence the day
after when cells were transfected with either a 50 nmol/L siRNA targeting HKII (Hs01_00080105, Sigma)
or a negative control (SIC001, Sigma) using Lipofectamine RNAiMAX Reagent (Life Technologies,
Thermo Fisher Scientific) and Opti-MEM (Gibco) accordingly to the manufacturer’s instructions.
The functional analyses described were performed 3 days after transfection.
2.6. Radiolabeled Glucose Uptake Assay
Parental and PDR cells were seeded into a 6-well plate in basal culture conditions. Glucose uptake
was evaluated incubating the cells with a bu↵ered solution containing 0.2 µCi/mL [3H]-2-deoxyglucose
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(Perkin Elmer) for 15 min at 37  C. Cells were subsequently washed with cold PBS and lysed with
0.1 M NaOH. Incorporated radioactive glucose derived signal was measured by liquid scintillation
counting and normalized on protein content.
2.7. Gas Chromatography–Mass Spectrometry (GC–MS)
Gas chromatography–mass spectrometry (GC–MS) analysis was previously described [14].
Briefly, for SCAN mode, 1 ⇥ 106 cells were collected and subjected to extraction using a mixture of
CHCl3:MeOH:H2O (1:1:1), before quenching with ice-cold MeOH:H2O (1:1) containing norvaline
(Sigma), used as internal standard. CHCl3 was then added, and the samples were vortexed at 4  C
for 30 min, centrifuged at 3000⇥ g for 10 min, and the aqueous phase was collected and allowed to
evaporate at room temperature. Dried polar metabolites were dissolved in 60 µL of 2% methoxyamine
hydrochloride (Sigma) in pyridine (Thermo Fisher Scientific), and held at 30  C for 2 h. After dissolution
and reaction, 90 µLN-Trimethylsilyl-N-methyl trifluoroacetamide (MSTFA) + 1% trimethylchlorosilane
TMCS (Sigma) were added and samples were incubated at 37  C for 60 min. Gas chromatographic
runs were performed with helium as carrier gas at 0.6 mL/min. The split inlet temperature was set
to 250  C and the injection volume of 1 µL. A split ratio of 1:10 was used. The GC oven temperature
ramp was from 60 to 325  C at 10  C/min. The data acquisition rate was 10 Hz. For the Quadrupole,
an Electron Ionization (EI) source (70 eV) was used, and full-scan spectra (mass range from 50 to
600) were recorded in the positive ion mode. The ion source and transfer line temperatures were set,
respectively, to 250 and 290  C.
For selected ion monitoring (SIM) mode MS analysis, cells were scraped in 80% methanol
and phase separation was achieved by centrifugation at 4  C. The methanol-water phase
containing polar metabolites was separated and dried using a vacuum concentrator. Dried polar
metabolites were dissolved in 20 µL of 2% methoxyamine hydrochloride in pyridine (Pierce,
Thermo Fisher Scientific) and held at 37  C for 2 h. After dissolution and reaction,
80 µL N-tert-Butyldimethylsilyl-N-methyltrifluoroacetamide with 1% tert-Butyldimethylchlorosilane
MBTSTFA + 1% TBDMCS (Thermo Fisher Scientific) was added and samples were incubated at 60  C
for 60 min. Gas chromatographic runs were performed with helium as carrier gas at 0.6 mL/min.
The split inlet temperature was set to 250  C and the injection volume of 1 µL. The GC oven temperature
ramp was from 70 to 280  C. The first temperature ramp was from 70 to 140  C at 3  C/min. The second
temperature ramp was from 140 to 180  C at 1  C/min. Finally, the latest temperature ramp was from
180 to 280  C at 3  C/min. The data acquisition rate was 10 Hz. For the Quadrupole, an EI source
(70 eV) was used. The ion source and transfer line temperatures were set, respectively, to 250 and
290  C. For the determination of relative metabolite abundances, the integrated signal of all ions for
each metabolite fragment was normalized by the signal from norvaline and the per cell number.
2.8. Metabolomics Data Analysis
Chromatograms and spectra were initially analyzed using MassHunter Qualitative Analysis and
then processed using Profinder (Agilent Technologies, Cernusco sul Naviglio, Italy). Profinder returned
3624 aligned compounds using the following filters: m/z range (100–1000 m/z), absolute peak height
(>10,000 counts), number of ions required ( 5 ions).
Data generatedwere exported as compound exchange format files (.CEF file) and subjected toMass
Profiler Professional (MPP, Agilent Technologies). Data were median log transformed and subjected to
statistical analysis using Tukey’s honest significant di↵erence (HSD)-corrected analysis of variance
(ANOVA). Di↵erentially expressed m/z entities were selected to have an adjusted p-value  0.05 in
the ANOVA test, with a Benjamini and Hochberg correction. This analysis returned 1953 entities
that were then further processed using MPP for the principal component (PCA) and for clustering
analyses. Unsupervised hierarchical clustering was performed using the list of di↵erentially expressed
entities (i.e., metabolites) and conditions (resistance versus sensitivity) and Euclidean correlation and
Ward’s linkage rule were used as measure of similarity. Metabolites identification was performed using
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MPP and Fihen Metabolomics retention time locking (RTL) library (Agilent G1676AA) as a reference.
A Table with the identification output is provided as Supplementary Table S1.
2.9. Seahorse XFe96 Metabolic Assays
Cells were seeded in XFe96 cell culture plates with 1.5–2 ⇥ 104 cells per well and subjected to the
extracellular flux (XF) glycolytic rate assay and/or to the XF mito stress test. For the XF glycolytic
rate assay, PDR cells were maintained in routine culture conditions while PDS cells were either left
in basal medium or challenged for 72 h with 1 µM palbociclib to evaluate the e↵ects of palbociclib
acute treatment. After 3 days, media were replaced with XF assay medium supplemented with 1 mM
pyruvate, 2 mM glutamine, 10 mM glucose and incubated at 37  C in a non-CO2 incubator for 1 h before
the analysis. The glycolytic rate assay discriminates between the extracellular acidification (ECAR)
that is dependent on mitochondrial-derived CO2 and that of glycolysis by concomitantly measuring
the amount of oxygen consumed (OCR) by the cells, hence calculating the total proton e✏ux rate (PER).
This analysis is performed in real-time by measuring ECAR and OCR after Rotenone/Antimycin A
(0.5 µM) and 2-DG (50 mM) administration. For the XF Mito Stress test, cells were cultured in a basal
medium that was replaced 24 h post-seeding with XF base medium supplemented with 25 mM glucose,
2 mM glutamine and 1 mM sodium pyruvate. Cells were incubated for 1 h at 37  C in a non-CO2
incubator before the analysis. Mito Stress test analysis reveals basal respiration, maximal respiration
and the ability of the cells to exploit mitochondrial oxidative metabolism. This analysis is performed
by real-time measurement of ECAR and OCR after a sequence of compounds that interfere with the
electron transport chain: oligomycin (1 µM), carbonyl cyanide-4 (trifluoromethoxy) phenylhydrazone
(FCCP) (1 µM) and Rotenone/Antimycin A (0.5 µM). Protein quantification was used to normalize the
results of Mito stress and Glycolytic rate test.
2.10. Analysis of Human Datasets
Survival analysis was performed using Kaplan-Meier curve log-rank testing, using Cuto↵
finder [15] for best (202934_at) HK2 high- and low-expression selection. The curated dataset of ER+
breast cancers was created using Km-plotter [16]. The relapse-free survival (RFS) data of patients
belong to the following datasets: GSE45255, GSE37946, GSE2603, GSE21653, GSE20711, GSE19615,
GSE17907, GSE16391, E-MTAB-365. The overall survival (OS) data of patients belong to the following
datasets: GSE45255, GSE37946, GSE20711. HK2 expression is frompatient-derivedmaterial at diagnosis
analyzed accordingly to the original studies. Information on normalization methods and multivariate
analysis are available online at the KMplotter website and have been described in [16].
2.11. Statistical Analysis
Statistics were performed using Prism 8 (GraphPad Software, San Diego, CA, USA). Unless
stated otherwise, all numerical data are expressed as the mean ± standard error of the mean (SEM).
All experiments were conducted at least 3 times independently, with 3 or more technical replicates for
each experimental condition tested. Unless stated otherwise, comparisons between 2 groups were
made using the two-tailed, unpaired Student’s t-test. Comparisons between multiple groups were
made using one-way ANOVA. Bonferroni and Dunnett post-testing analysis with a confidence interval
of 95% was used for individual comparisons as reported in figure legends. Multivariate Cox analyses
on the cohort of patients analyzed were generated using KM-plotter. Statistical significance was
defined as: * p < 0.05; ** p < 0.01; *** p < 0.001, **** p < 0.0001; when di↵erences were not statistically
significant or the comparison not biologically relevant no indication were reported in the figures.
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3. Results
3.1. Palbociclib Impacts on the Expression of Key Players Involved in Glucose Catabolism
To investigate the metabolic reprogramming occurring during response and at resistance to
palbociclib, we first performed gene expression and protein analysis of key metabolic players involved
in glucose metabolism on a panel of palbociclib sensitive (PDS) cells, in the presence or absence of
1 µM palbociclib, and PDR derivatives. The panel contains ER+ cell lines with di↵erential HER2
status (i.e., ZR75-1 and T47D are ER+/HER2 , BT474 and MDA-MB-361 are ER+/HER2+) and has
been previously characterized [13]. However, no common transcriptional programs were associated
with palbociclib resistance, since cell-type specific features seem to dictate unsupervised hierarchical
clustering based on the transcriptomic analysis as detailed in [13]. Since CDK4/6 inhibitors have been
reported to perturb glucose dependent metabolism [17], we initially monitored in the isogenic cell
lines’ established traits of cells undergoing aerobic glycolysis.
qRT-PCR analysis revealed enhanced expression levels of GLUT1 in all the PDR cells analyzed
(Figure 1A). GLUT1 is found overexpressed and can contribute to enhanced glucose uptake in many
tumor cells [18]. However, the expression of the rate-limiting enzyme of the glycolytic pathway
hexokinase 2 (HK2) was di↵erently regulated in PDR cells, depending on HER2 amplification status.
Indeed, HER2  ZR75-1-PDR and T47D-PDR cells showed a modest but significant decrease in
HK2 expression (Figure 1B, left), whereas HER2+ PDR cell lines (i.e., BT474 and MDA-MB-361)
increased its expression (Figure 1B, right) compared to their PDS counterpart. Interestingly, palbociclib
administration to PDS cells induced a similar gene expression pattern forHK2 andGLUT1 (Figure 1A,B),
suggesting that acute (3-day) treatment may promote a metabolic phenotype switch which favors
therapy resistance. However, for the sake of completeness, palbociclib administration was shown to
induce growth arrest and senescence in the sensitive cells [13] and therefore this response may be
potentially linked to change in the cell proliferation rate. HK2 expression changes observed in PDR
cells and palbociclib-treated parental cells were confirmed at the protein level (Figure 1C). However,
we also know that (i) di↵erent isoforms of HK may be expressed and therefore being involved in
this rate-limiting reaction and (ii) HK2 expression does not directly measure HK enzymatic activity,
hence the potential discrepancies observed at mRNA and protein expression levels between HK2 and
GLUT1 render the identification of glycolysis dependency di cult and should be validated at the
functional level. Since enhanced glucose uptake may be a prerogative of cells that experience aerobic
glycolysis, we investigated the levels of monocarboxylates transporters MCT1 and MCT4 that, despite
having di↵erent a nity for lactate (MCT1: Km ~3.5–10 mM, MCT4: Km ~22–28 mM) [19], can both
function as lactate exporters in glycolytic cells, i.e., when lactate and pH gradient are driving lactate
e✏ux [20]. Interestingly, western blot analysis showed enhanced levels of either MCT1 or MCT4 in
ER+/HER2+ PDR cells when compared to the sensitive counterpart, whereas decreased levels of MCT1
or MCT4 were observed in the ER+/HER2  PDR cells (Figure 1C and Supplementary Figure S1A).
Palbociclib acute treatment induced a decrease of MCT1 or MCT4 levels in the ER+/HER2  PDS cell
lines and a small enhancement was observed in the ER+/HER2+ PDS cells (Figure 1C).
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Figure 1. Palbociclib impacts on the expression of key players involved in glucose catabolism. (A, B)
Palbociclib-resistant (PDR) and parental sensitive (PDS) cells, in presence or absence of 1µM palbociclib
(PD), were subjected to quantitative real-time polymerase chain reaction (qRT-PCR) analysis using
the assays described in the figure. Relative expression is shown using the PDS cells as comparator.
Each dot represents a biological replicate. Gray shades are used for PDS cells, blue shades when PD
is administrated to human epidermal growth factor receptor 2 (HER2 ) cells (either PDS or PDR),
red shades when PD is administrated to HER2+ cells (either PDS or PDR). Data represent means ±
standard errors of the mean (SEMs). One-way analysis of variance (ANOVA); Bonferroni corrected;
* p < 0.05; ** p < 0.01; *** p < 0.001; **** p < 0.0001. (C) Total protein lysates from PDS (either in the
presence or absence of 1 µM palbociclib, PD) and PDR cells were subjected to Western blot analysis,
as indicated.
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3.2. Resistant Cells Show Comparable Growth Rates When Compared to Sensitive Counterpart While
Increasing Glucose Uptake
We then investigated whether the changes in the expression levels of the metabolic players could
have a functional implication. Indeed, the increased GLUT1 expression observed in the PDR cells is
paralleled by enhanced glucose uptake, as monitored by tracing analysis using radiolabeled glucose
(Figure 2A). However, despite 3-day palbociclib treatment enhancedGLUT1 expression levels also in the
sensitive cells, we did not observe enhanced glucose uptake in these conditions (Figure 2A). Importantly,
the changes observed in metabolic genes expression and glucose uptake were not dependent on the
survival of the sensitive and resistant cells, since no significant di↵erences in growth rate were observed
in a 5-day time-course experiment (Figure 2B and Supplementary Figure S1B), in line with a previous
report [13]. To avoid any confounding e↵ects of proliferation, all the metabolic-related analyses
performed in the current study were performed between 24 and 72 h.
Figure 2. Resistant cells show comparable growth rates when compared to sensitive counterpart while
increasing glucose uptake. (A) 14C-glucose uptake was measured in PDS (either in presence or absence
of 1 µM palbociclib, PD) and PDR cells. The relative uptake capacity is shown using PDS cells as
comparator. Each dot represents a biological replicate. Gray shades are used for PDS cells, blue shades
when PD is administrated to HER2  cells (either PDS or PDR), red shades when PD is administrated to
HER2+ cells (either PDS or PDR). Data represent means ± SEMs. One-way ANOVA; Dunnett corrected;
* p < 0.05; ** p < 0.01; *** p < 0.001; **** p < 0.0001. (B) No significant reduction in cell survival between
PDS and PDR derived cells was observed by cell counting within the 5-day time range. Data represent
means ± SEMs. Two-way ANOVA; Bonferroni corrected.
3.3. Human Epidermal Growth Factor Receptor 2 (HER2) Status Impacts on Glucose Catabolism and Reveals
Di↵erent Glucose Dependency during Acute and Chronic Palbociclib Administration
To evaluate whether the enhanced glucose uptake of the PDR cells was paralleled by increased
exploitation of glucose-dependent catabolism, we performed Seahorse analysis. In particular, glycolytic rate
Cells 2020, 9, 668 9 of 22
assay allows discriminating between the Extracellular Acidification Rate (ECAR) that is dependent on
mitochondrial-derived CO2 and that of glycolysis, by concomitantly measuring the Oxygen Consumption
Rate (OCR) by the cells, hence calculating the total Proton Efflux Rate (PER). Cells were subjected to
real-time measurement of ECAR and OCR following mitochondrial function inhibition using Rotenone and
Antimycin A (Rot/AA) followed by glycolysis inhibition using 2-deoxyglucose (2-DG).
ER+/HER2  ZR75-1 and T47D PDR cells significantly decreased the overall glycoPER levels when
compared to the PDS counterpart (Figure 3A,C). Accordingly, basal and compensatory glycolysis were
significantly decreased (Figure 3B,D). Comparable data were obtained in the ER+/HER2  MCF7 cells
(Supplementary Figure S1C). Conversely, the ER+/HER2+ BT474 and MDA-MB-361 cells enhanced
glycoPER levels (Figure 3E,G) and subsequently their basal and compensatory glycolysis (Figure 3F,H)
when they become PDR. M oreover, palbociclib administration reduces basal and compensatory
glycolysis in both HER2  and HER2+ sensitive cells, suggesting that the metabolic behavior in response
to palbociclib in the sensitive cells may be di↵erent from the metabolic phenotype of the resistant cells,
at least in the ER+/HER2+ subset.
We have reported previously that during endocrine therapy resistance cells becomemore glycolytic
while acquiring metabolic plasticity, a feature that renders metabolic targeting challenging [21,22].
Since aerobic glycolysis seems to play an important role in palbociclib resistance, we evaluated
whether the PDR cells could exploit mitochondrial oxidative phosphorylation under metabolic stress
conditions. OCR was measured in real-time following oligomycin, FCCP and Rotenone/Antimycin A,
administrated at di↵erent time points to evaluate basal and maximal oxidative respiration. In line
with the glycoPER data, HER2  PDR ZR75-1 and T47D cells displayed enhanced levels of OCR and
subsequent basal and maximal respiration when compared to the sensitive counterpart (Figure 4A–D).
Conversely, HER2+ PDR BT474 and MDA-MB-361 cells showed reduced OCR, basal and maximal
oxidative metabolism (Figure 4E–H), hence suggesting that the reduced respiration is counteracted
by the enhanced aerobic glycolysis described by the glycolytic rate assay (Figure 3). Together these
data highlight the existence of a metabolic reprogramming that is dependent on the HER2 status of
the ER+ cell lines analyzed, suggesting potential therapeutic scenarios that may di↵er based on the
expression of HER2 on the subset of the cells analyzed. These data are in line with previous studies
showing that targeting glycolysis may have a synergistic e↵ect in HER2+ breast cancer in combination
with anti-HER2 therapy [23–25].
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Figure 3. HER2 status impacts on glucose catabolism and reveals di↵erent glucose dependency during
acute and chronic palbociclib administration. (A, C, E, G) PDS (either in presence or absence of 1 µM
palbociclib, PD) and PDR cells were subjected to seahorse XFe96 glycolytic rate analysis and glycolytic
proton e✏ux rate (glycoPER)) was measured in real time and normalized on protein levels. (B, D,
F, H) Basal and compensatory (i.e., when electron transport chain is impaired) glycolytic capacity
was calculated as described in Method Details, based on the extracellular acidification rate (ECAR)
and oxygen consumption rate (OCR) after the administration of the respiratory complex I inhibitor
rotenone, together with the respiratory complex III inhibitor antimycin A following by the glycolysis
inhibitor 2-deoxy-glucose (2-DG). Data represent means ± SEMs. Each dot represents at least three
technical replicates from three biological replicates. Blue dots are from HER2  cells, red from HER2+.
One-way ANOVA; Dunnett’s corrected; **** p < 0.0001.
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Figure 4. HER2 status impacts on glucose dependent oxidative phosphorylation in palbociclib
resistance. (A, C, E,G) PDS and PDR cells were subjected to Seahorse XFe96 Mito Stress Test analysis
and OCR was measured in real time and normalized on protein levels. (B, D, F, H) Basal and
maximal respiration was calculated as described in Method Details, based on the OCR after the
administration of the adenosine triphosphate ATP synthase inhibitor oligomycin, the proton uncoupler
carbonilcyanide p-triflouromethoxyphenylhydrazone (FCCP), and the respiratory complex I inhibitor
rotenone, together with the respiratory complex III inhibitor antimycin A. Each dot represents at least
three technical replicates from three biological replicates. Data represent means ± SEMs. One-way
ANOVA; Dunnett’s corrected; *** p < 0.001; **** p < 0.0001.
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3.4. Targeting Glycolysis Resensitizes ER+/HER2+ Palbociclib-Resistant (PDR) Cells to Palbociclib
Since glucose catabolism seems to be a major contributor to palbociclib response and emergence of
palbociclib resistance, we interfered with the glycolytic pathway with an array of di↵erent approaches.
First, PDR cells were exposed to 2-DG, a compound that can be phosphorylated but is not further
metabolized by cells. 2-DG treatment reduces of ~20% the survival fraction of HER2  PDR cells when
compared to control untreated PDR cells (Figure 5A and Supplementary Figure S1D, blue symbols).
Importantly, the reduction after 2-DG treatment in the HER2+ PDR BT474 and MDA-MB-361 cells was
48% and 64% (Figure 5A, red symbols), respectively. Comparable results were obtained when cells
were cultured in the absence of glucose (Figure 5B and Supplementary Figure S1D) and in a medium
in which glucose is replaced by galactose (Figure 5C and Supplementary Figure S1D), a condition that
increases reliance on oxidative phosphorylation for energy production [26]. To investigate whether the
presence of palbociclib was necessary to induce the survival changes when glycolysis was targeted,
the same approach was performed in PDR cells in the absence of palbociclib. Treatments were e↵ective
only when palbociclib was co-administrated to the cells (Supplementary Figure S2A). These results
support the concept that glycolysis targeting resensitizes PDR cells to palbociclib treatment. To confirm
the crucial role of glycolysis in palbociclib resistance of the HER2+ cells, we further targeted glycolysis
by silencing HK2 in BT474 and MDA-MB-361 PDR cells (Figure 5D). Importantly, HK2 targeting
reduces cell survival of both BT474 PDR (Figure 5E) andMDA-MB-361 PDR (Figure 5F), confirming the
data generated by non-genetic interference.
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Figure 5. Targeting glycolysis resensitizes ER+/HER2+ PDR cells to palbociclib. PDR cells were either
treated for 3 days in the presence of 2-DG (A), glucose-deprived medium (B) or in a medium in which
glucose is replaced by galactose (C). Data are presented as fold change survival fraction of treated versus
vehicle-treated or basal-cultured cells. Each dot represents at least three technical replicates from three
biological replicate. Shades of blue dots are for HER2  PDR cells, shades of red dots for HER2+ PDR
cells. Data represent means ± SEMs and were compared to vehicle-treated or basal-cultured conditions
using one-way ANOVA; Dunnett corrected; * p < 0.05; ** p < 0.01; *** p < 0.001; **** p < 0.0001. (D) Total
protein lysates from ER+/HER2+ PDR cells transfected with the oligos as described in the figure for 72 h
were subjected to Western blot analysis, as indicated. (E, F) Survival fraction changes were measured
in cells transfected as indicated in the Figure. Each dot represents at least three technical replicates
from three biological replicates. Data represent means ± SEMs and were compared to non-targeting
control siRNA (siCTR)-treated cells using Student t test; **** p < 0.0001.
3.5. Targeting Glycolysis Potentiates Palbociclib E↵ects on ER+/HER2  Parental Cells
Since ER+/HER2  PDS cells displayed high glycolytic dependency accordingly to the metabolic
characterization (Figures 1–3), we hypothesized that impairing glycolysis in the parental cells could impact
the survival fraction of those cells and potentiate the effects of the palbociclib. Indeed, 2-DG administration
(Figure 6A and Supplementary Figure S1D), glucose-deprived medium (Figure 6B and Supplementary
Figure S1D) and galactose-containing medium (Figure 6C and Supplementary Figure S1D) had a higher
impact on cell survival of ER+/HER2  MCF7, ZR75-1 and T47D PDS cells when compared to ER+/HER2+
parental cells. Accordingly, we hypothesized that combining palbociclib with a glycolysis inhibitor may
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be more efficient than using palbociclib as monotherapy. Indeed, 2-DG administration (Figure 6D,G and
Supplementary Figure S1D), glucose-deprived medium (Figure 6E,H and Supplementary Figure S1D)
and galactose-containing medium (Figure 6F,I and Supplementary Figure S1D) enhanced the effect of
palbociclib in inhibiting ER+/HER2  cell survival. No impact was observed in the ER+/HER2+ PDS cell
lines (Supplementary Figure S3).
Figure 6. Targeting glycolysis potentiates palbociclib e↵ects on ER+/HER2  parental cells. PDS cells
were either treated for 3 days in the presence of 2-DG (A), glucose-deprived medium (B) or in a medium
in which glucose is replaced by galactose (C). Data are presented as fold change survival fraction
of treated versus vehicle-treated or basal-cultured cells. Each dot represents at least three technical
replicates from three biological replicates.
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Data represent means ± SEMs and were compared to vehicle-treated or basal-cultured conditions using
one-way ANOVA; Dunnett corrected; * p < 0.05; ** p < 0.01; *** p < 0.001; **** p < 0.0001. ER+/HER2 
PDS cells were either treated for 3 days in the presence of 2-DG (D, G), glucose-deprived medium
(E, H) or in a medium in which glucose is replaced by galactose (F, I) either in presence or absence
of 1 µM palbociclib (PD). Data are presented as fold change of the survival fraction of treated versus
vehicle-treated or basal-cultured cells. Each dot represents at least three technical replicates from three
biological replicates. Gray shades are used for PDS cells, blue dots when PD is administrated to HER2-
PDS cells. Data represent means ± SEMs and were compared to vehicle-treated or basal-cultured
conditions using one-way ANOVA; Dunnett corrected; * p < 0.05; ** p < 0.01; **** p < 0.0001.
3.6. Metabolomic Profiling Identifies a Distinct Intracellular Metabolites Pattern between HER2+ and HER2 
ER+ PDR Cells
The functionalmetabolicprofileof thePDRcells suggests that the four isogenic cell linesarecharacterized
by different metabolic behavior at the time of palbociclib resistance. These metabolic differences may
result in a different intracellular metabolites composition. To address this hypothesis, we performed
gas chromatography-mass spectrometry (GC–MS) analysis. Three independent biological replicates of
PDS and PDR cell lines were subjected to cell lysis, metabolites extraction, and subsequent derivatization
before processing to GC–MS. The chromatogram and them/z entities of each sample were matched to the
Fiehn library that allows, after Mass Profiler Professional software processing, the identification of ~1K
metabolites [27]. However, it was not possible to identify all them/z entities generated by GC–MS, although
differentially expressed between different samples (Supplementary Table S1).
Unsupervised hierarchical cluster analysis shows that the samples divide into HER2  and HER2+
breast cancer cell lines and that, within these 2 groups, the samples cluster according to palbociclib
sensitivity and resistance (Figure 7A). Importantly, Venn diagrams of the di↵erentially regulated
metabolites show little overlap between the di↵erent cell lines analyzed (Supplementary Figure S4 and
Supplementary Table S1), reinforcing the concept that the genetic background (i.e., HER2 status) of
each cell line has a strong influence on the metabolomic profile. Importantly, the di↵erences observed
in the glycolysis dependencies of the in vitro models described in the study could be recapitulated
by monitoring the intracellular levels of lactate, pyruvate and glucose-6-phosphate, rate-limiting
metabolites in sustaining the glycolytic flux. Metabolomic analysis performed using selected ion
monitoring mode showed that the relative abundance of intracellular lactate is reduced in HER2  T47D
and ZR75-1 PDR cells (Figure 7B) and increased in HER2+ MDA-MB-361 and BT474 PDR cells when
compared to parental PDS counterpart (Figure 7C). A comparable trend was observed in the levels
of glucose-6-phospate (Figure 7B,C). Conversely, pyruvate levels were reduced in MDA-MB-361 and
BT474 PDR cells and increased in T47D and ZR75-1 PDR cells when compared to PDS cells (Figure 7B,C).
The reliance on potential exploitation of fermentation of the analyzed cells can be monitored by the
lactate/pyruvate ratio (Supplementary Figure S5) that supports the functional metabolic analysis
described in Figures 1–6, highlighting enhanced glycolysis dependency in the MDA-MB-361 and
BT474 PDR cells and reduced in the T47D and ZR75-1 PDR cells, when compared to the parental
counterpart. Accordingly, TCA intermediates citrate, succinate, fumarate and malate were enhanced in
the ER+/HER2  PDR cells and decreased in the ER+/HER2+ PDR cells, when compared to the parental
counterpart (Supplementary Figure S6).
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Figure 7. Metabolomic profiling identifies a distinct intracellular metabolites pattern between HER2+
and HER2  ER+ PDR cells. (A) Unsupervised hierarchical clustering and heat map of the entities
derived by the cell lysis, metabolites extraction, and subsequent derivatization before processing to gas
chromatography–mass spectrometry (GC–MS) from three independent biological replicates of PDS
and PDR cell lines. (B, C) Intracellular relative abundance of the following metabolites in ER+/HER2 
(B) and in ER+/HER2+ cells (C): glucose-6-phosphate, lactate and pyruvate. * p < 0.05; ** p < 0.01;
*** p < 0.001; **** p < 0.0001.
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3.7. Enhanced HK2 Expression Levels Identify a Subset of Poor Prognosis Tumors
Since we could not retrieve a large dataset of patients that receive palbociclib and for which
the clinical follow-up data and transcriptomic analysis are available, we investigated whether the
glycolytic dependency is correlated to worse prognosis in the ER+/HER2+ subgroup which has been
shown by the in vitro analysis to be dependent on glycolysis when resistance is acquired. Therefore,
we explored the prognostic value of HK2, a key gene whose expression is an established hallmark
of glucose catabolism [28]. We have already reported that breast cancers that express higher levels
of HK2 are characterized by worse prognosis in a cohort of ER+ breast cancer patients that received
ET [21]. Here we investigated the prognostic value of HK2 in a cohort of /ER+/HER2+ breast cancers
and identified that higher expressing HK2 tumors are characterized by reduced overall survival (OS,
hazard ratio (HR) = 8.26, p = 0.001; Figure 8A) and relapse-free survival (RFS, HR = 2.33, p = 0.041;
Figure 8B). Crucially, HK2 prognostic value was independent of tumor proliferation as assessed by
multivariate cox analysis using MKI67, ESR1 and HER2 expression levels (Table 1). These results
suggest that HK2 expression may be a further trait of aggressiveness in ER+/HER2+ tumors hence
making those patients eligible for a more stringent follow-up or candidate to potential combinatorial
therapy approaches.
Figure 8. Enhanced HK2 expression levels identify a subset of poor prognosis tumors. Kaplan–Meier
analysis of overall survival (A) and relapse free survival (B) of a curated cohort of ER+/HER2+ patients
divided into high- and low-expressing, as described in Method Details, for HK2 expression. The hazard
ratio (HR), interval of confidence and log-rank Mantel–Cox p value are shown.
Table 1. Multivariate Cox regression analysis (overall survival (OS), A) and (relapse-free survival (RFS), B).
Parameters p Value Hazard Ratio (HR)
A
MKI67 0.909 0.93 (0.28–3.12)
ESR1 0.118 0.11 (0.01–1.75)
HER2 (ERBB2) 0.340 0.55 (0.16–1.88)
HK2 0.0082 16.67 (2.07–134.21)
B
MKI67 0.739 0.87 (0.37–2.03)
ESR1 0.0192 0.15 (0.03–0.73)
HER2 (ERBB2) 0.3505 0.66 (0.27–1.59)
HK2 0.0188 2.99 (1.2–7.47)
4. Discussion
Metabolic reprogramming is an established trait of cancer cells and is implicated in therapy
response and resistance [22]. In the current study we have used a previously characterized panel
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of isogenic ER+ breast cancer cell lines either sensitive or made resistant by chronical palbociclib
exposure [13] and investigated their glucose metabolism. Although clinically CDK4/6 inhibitors
are currently approved in combination with ET, the use of cells that are resistant to palbociclib (i.e.,
monotherapy) can generate biological data without the confounding e↵ect of the additional agent
used in the combinatorial treatment (i.e., ET or anti-HER2 therapy). This approach has been used
previously and generated clinically relevant results, identifying cyclin E1 overexpression and Rb loss as
genetic traits of palbociclib resistance [13,29,30]. Importantly, mammalian target of rapamycin complex
1 (mTORC1) activation is also reported to play an important role in the resistance mechanism and,
currently, PI3K inhibitors (i.e., blocking PI3K/mTOR pathway) are in clinical trials in combination with
CDK4/6 inhibitors [31]. Importantly, mTOR activation has also been reported to enhance glycolytic
traits of the resistant cells, suggesting that glycolytic function may be under PI3K/mTOR signaling
control in cancer and other pathologies [17].
The data herein presented highlight a glucose-dependency that is influenced by the genetic
background of the cell lines used, i.e., HER2 amplification. In particular, ER+/HER2  cell lines
are characterized by high glucose exploitation when sensitive to palbociclib, and this dependency
can be e↵ectively targeted, hence potentiating the anti-proliferative e↵ect of the drug. Conversely,
ER+/HER2+ cells show a significant increase in glucose catabolic dependency when becoming resistant,
and glycolysis targeting by multiple approaches is able to resensitize PDR cells to the initial therapy
(Figure 9).
Figure 9. Graphical representation of the central carbon metabolic reprogramming during palbociclib
resistance in ER+/HER2+ and ER+/HER2  breast cancer cells.
Often, in tumor cells, glucose is partially oxidized to pyruvate and subsequently fermented to
lactate, even in the presence of oxygen [32,33]. This glucose metabolic exploitation is fundamental
in tumorigenesis since it could provide both ATP and building blocks by fueling anabolic pathways
that originate from glycolytic intermediates. It has been reported previously that the cyclin D1-CDK4
and cyclin D3-CDK6 pairs can regulate glucose metabolism [10,12] and that palbociclib administration
reduces glucose metabolism in triple negative breast cancer in vitro models [34]. The rationale
for investigating the glucose metabolic reprogramming associated with resistance to palbociclib is
also supported by preclinical studies showing that (i) CDK4/6 inhibition enhances central carbon
metabolism, the number of mitochondria and reactive oxygen species (ROS) production, a phenomenon
associated with enhanced mTORC1 activity in pancreatic cancer models [17] and that (ii) CDK4/6
inhibitors e cacy is potentiated by autophagy inhibition in Rb-positive solid tumors [9]. Although the
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initial (basal) characterization of glucose uptake and GLUT1 expression levels suggested a common
mechanism of resistance since all the cell lines showed enhanced glucose avidity, independently of
HER2 status, further functional metabolic analysis revealed a di↵erent metabolic phenotype. Indeed,
Seahorse analyses showed that glycolysis dependency was reduced in ER+/HER2  PDR cells while
significantly increased in the ER+/HER2+ PDR cell lines. Accordingly, the exploitation of oxidative
phosphorylation is inversely correlated with the glycolytic dependency, as monitored by oxygen
consumption under basal and mitochondrial stress conditions. The discrepancies observed between
glucose uptake and glycolysis dependency may be due to the fact that the enhanced glucose uptake
observed in the ER+/HER2  PDR cells does not result in increasing glucose catabolism but rather
fuels alternative (i.e., anabolic) pathways that diverge from glycolytic intermediates such as pentose
phosphate, hexosamine and/or serine biosynthesis. Indeed, palbociclib treatment in MCF7 has been
shown to enhance pentoses levels, a readout of the oxidative branch of the pentose phosphate
pathway [35]. These anabolic pathways would provide building blocks necessary for proliferating
cells and nicotinamide adenine dinucleotide phosphate (NADPH) essential to counteract the potential
oxidative stress enhancement that occurs in cells under therapeutic pressure.
Themetabolic di↵erences described have been exploited by targeting the priming step of glycolysis
(i.e., HK2) and glycolytic dependencies in di↵erent contexts thus suggesting that targeting glucose
metabolism may be more e↵ective in the sensitive setting in the ER+/HER2  subset while it can
re-sensitize ER+/HER2+ PDR breast cancers to the initial therapy. Importantly, the di↵erences described
could also point to investigate the consequence of targeting the oxidative metabolism (e.g., targeting
complexes in the electron transport chain) in the ER+/HER2  resistant clinical scenario, more likely to
occur in the near future, since palbociclib is currently used in the ER+/HER2  cohort of patients.
Although ER+/HER2+ breast cancers are not currently eligible for CDK4/6 inhibitor therapy [36],
preclinical data have shown that cyclin D1/CDK4/6/pRB axis may be deregulated and represent
a key mechanism driving resistance to anti-HER2 therapies [37]. Importantly, breast cancer
cells that survive lapatinib treatment show enhanced activation of cyclin D1/CDK4 complex,
hence suggesting the importance of this pair for anti-HER2 response and subsequent relapse.
A series of clinical trials are now enrolling ER+/HER2+ patients to test the e cacy of approaches
combining palbociclib and anti-HER2 therapies in breast cancer (i.e., ClinicalTrials.gov identifier:
NCT02448420-PATRICIA, NCT02530424-NA-PHER2 and NCT03644186-TOUCH) either as doublets or
more complex combinations with the addition of endocrine therapies.
The metabolic analysis herein described reveals that enhanced glycolysis dependency might
be a trait of ER+/HER2+ tumors that are prone to acquire resistance to palbociclib. Importantly,
this propensity is revealed by monitoring HK2 expression levels, a trait that has been previously
reported to be intimately interconnected with aerobic glycolysis. Kaplan–Meier analyses of overall
and relapse-free survival in ER+/HER2+ breast cancer patients revealed that HK2 high-expressing
tumors are characterized by worse prognosis, independently of HER2, ESR1 and proliferation status
measured using MKI67 levels. However, these analyses do not directly prove the clinical significance
of HK2 as a predictive marker in palbociclib treated ER+ patients and should be further validated in
matched tissue biopsies obtained at diagnosis and at the time of disease progression on palbociclib
treatment. Moreover, preclinical studies should reveal whether favoring glycolysis in the sensitive
setting is su cient to desensitize cells to palbociclib, hence favoring resistance.
In conclusion, the current study demonstrates a role for glucosemetabolism in sustaining resistance
to palbociclib. The implications of these results are multiple: (i) targeting glucose dependency is
e↵ective in preclinical in vitromodels andwarrants further investigations; (ii) since glucosemetabolism
can be monitored in patients using 18F-fluorodeoxyglucose (18F-FDG) PET/CT, understanding the
correlation between 18F-FDG PET and palbociclib response could be a non-invasive methods to
better tailor personalized therapies and monitor therapy response; (iii) the data that emerged in the
HER2+ subset may help supporting biomarker discovery and potential treatment vulnerabilities in
ER+/HER2+ cancers treated with CDK4/6 inhibitors. The in vitro data herein described needs to be
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further confirmed in vivo to validate whether tumor metabolic features may have a potential clinical
value in palbociclib resistance either to follow up patients during their treatment or to develop new
therapeutic strategies in combination with CDK4/6 inhibitors.
Supplementary Materials: The following are available online at http://www.mdpi.com/2073-4409/9/3/668/s1:
Figure S1: ER+/HER2  MCF7 cells recapitulate the metabolic behaviour of the ER+/HER2  breast cancer cells;
Figure S2: PDR cells are re-sensitised to palbociclib when glycolysis is targeted; Figure S3: Targeting glycolysis
alone or in combination with PD in ER+/HER2+ PDS cells has nomajor impact when compared to palbociclib alone;
Figure S4: Commonly deregulated metabolites between the di↵erent PDR cell lines; Figure S5: Aerobic glycolysis
is enhanced in ER+/HER2+ and reduced in ER+/HER2  PDR cells when compared to PDS cells; Figure S6: TCA
intermediates are enhanced in ER+/HER2  and reduced in ER+/HER2+ PDR cells when compared to PDS cells;
Table S1: Di↵erentially expressed m/z entities between the di↵erent PDS and PDR cell lines.
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